70 related articles for article (PubMed ID: 35313664)
21. Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients.
Easdale S; Shea R; Ellis L; Bazin J; Davis K; Dallas F; Thistlethwayte E; Ethell M; Potter M; Arias C; Anthias C; Nicholson E
Transplant Cell Ther; 2021 Oct; 27(10):880.e1-880.e4. PubMed ID: 34293520
[TBL] [Abstract][Full Text] [Related]
22. Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients.
Marion O; Del Bello A; Abravanel F; Faguer S; Esposito L; Laure Hebral A; Bellière J; Izopet J; Kamar N
Transplant Direct; 2022 Jan; 8(1):e1248. PubMed ID: 34966837
[TBL] [Abstract][Full Text] [Related]
23. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
24. Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
Mazzola A; Todesco E; Drouin S; Hazan F; Marot S; Thabut D; Varnous S; Soulié C; Barrou B; Marcelin AG; Conti F
Clin Infect Dis; 2022 Mar; 74(6):1093-1096. PubMed ID: 34166499
[TBL] [Abstract][Full Text] [Related]
25. Cellular and Humoral SARS-CoV-2 Vaccination Responses in 192 Adult Recipients of Allogeneic Hematopoietic Cell Transplantation.
Meyer T; Ihorst G; Bartsch I; Zeiser R; Wäsch R; Bertz H; Finke J; Huzly D; Wehr C
Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366291
[TBL] [Abstract][Full Text] [Related]
26. Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.
Al Jurdi A; Gassen RB; Borges TJ; Solhjou Z; Hullekes FE; Lape IT; Efe O; Alghamdi A; Patel P; Choi JY; Mohammed MT; Bohan B; Pattanayak V; Rosales I; Cravedi P; Kotton CN; Azzi JR; Riella LV
Front Immunol; 2022; 13():838985. PubMed ID: 35281011
[TBL] [Abstract][Full Text] [Related]
27. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
Front Immunol; 2022; 13():832501. PubMed ID: 35281023
[TBL] [Abstract][Full Text] [Related]
28. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC.
Jondreville L; D'Aveni M; Labussière-Wallet H; Le Bourgeois A; Villate A; Berceanu A; Bezsera SM; Thiebaut A; Boissard-Simonet M; Legrand M; Cornillon J; Rubio MT; Chevallier P; Nguyen S
J Hematol Oncol; 2022 Nov; 15(1):169. PubMed ID: 36443846
[TBL] [Abstract][Full Text] [Related]
29. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization.
Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D
J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832
[TBL] [Abstract][Full Text] [Related]
30. Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine.
Abravanel F; Marion O; Del Bello A; Beunon T; Romieu-Mourez R; Couat C; Pucelle M; Staes L; Guitard J; Esposito L; Faguer S; Kamar N; Izopet J
Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334985
[TBL] [Abstract][Full Text] [Related]
31. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
32. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
33. Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation.
Yeshurun M; Pasvolsky O; Shargian L; Yahav D; Ben-Zvi H; Rubinstein M; Sela-Navon M; Wolach O; Raanani P; Rozovski U
Clin Microbiol Infect; 2022 Feb; 28(2):303.e1-303.e4. PubMed ID: 34715348
[TBL] [Abstract][Full Text] [Related]
34. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
35. Antibody response after two doses of the SARS-CoV-2 Comirnaty vaccine in a Covid-19 positive and Covid-19 negative Italian healthcare workers cohort.
Sulejmani A; Giacobone C; Spiti S; Pozzobon C; Dominici R; Mascagni P; Falbo R; Brambilla P; Leoni V
Scand J Clin Lab Invest; 2022 Apr; 82(2):90-95. PubMed ID: 35195046
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
38. Haploidentical CD3
Ramanathan S; Veramendi-Espinoza L; Shillitoe B; Flinn A; Owens S; Williams E; Emonts M; Hambleton S; Burton-Fanning S; Waugh S; Flood T; Gennery AR; Slatter M; Nademi Z
J Allergy Clin Immunol Glob; 2023 Feb; 2(1):101-104. PubMed ID: 36210925
[TBL] [Abstract][Full Text] [Related]
39. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity.
Pourhassan H; La Rosa C; Chiuppesi F; Puing A; Aldoss I; Park Y; Zhou Q; Karpinski V; Faircloth K; Kaltcheva T; Johnson D; Francisco SO; Zaia JA; Nakamura R; Al Malki MM; Diamond DJ; Dadwal SS; Forman SJ
Blood Adv; 2022 Mar; 6(6):1645-1650. PubMed ID: 35008104
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
